1271.TWO SunWay Biotech Co., LTD.
- Market cap
- TWD 4.29B
- P/E
- 25.5x
- P/B
- 1.05x
- ROE
- 3.1%
- Dividend yield
- 1.87%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 1271.TWO undervalued?
Graham number1271.TWO trades 9.0% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
SunWay Biotech Co., LTD. fundamental analysis
No fundamental analysis for SunWay Biotech Co., LTD. yet.
SunWay Biotech Co., LTD. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About SunWay Biotech Co., LTD.
SunWay Biotech Co., LTD. engages in the research, development, manufacture and sales of Western medicines and health foods. The company offers red yeast rice and lactic acid bacteria products, as well as other health supplements; and wholesale and manufacturing of pharmaceutical products. It also research, designs, and manufactures Monascus purpureus NTU 568; Lactobacillus paracasei subsp. paracasei NTU 101; Monascus pilosus SWM-008 strain; Pediococcus acidilactici SWP-CGPA0…
Full company profileSunWay Biotech Co., LTD. financial statements
SunWay Biotech Co., LTD. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 74.2M | 71.4M | 109M | 172M | 314M | 380M | 425M | 571M | 970M | 993M |
| Gross Profit | 26.4M | 24.7M | 50.2M | 109M | 208M | 271M | 150M | 237M | 545M | 561M |
| Operating Income | -58.0M | -57.6M | -20.1M | 42.1M | 126M | 168M | 39.2M | 52.4M | 141M | 104M |
| EBITDA | -40.8M | -42.9M | -7.04M | 61.9M | 146M | 190M | 48.5M | 83.5M | 231M | 197M |
| Net Income | -62.2M | -68.8M | -13.5M | 38.2M | 126M | 169M | 30.0M | 46.1M | 119M | 102M |
| EPS | -2.10 | -2.27 | -0.43 | 1.15 | 3.94 | 4.91 | 1.49 | 1.50 | 1.96 | 1.69 |
| Balance Sheet | ||||||||||
| Total Assets | - | - | - | 317M | 511M | 608M | 478M | 3.66B | 3.79B | 4.46B |
| Total Liabilities | - | - | - | 38.6M | 46.5M | 60.6M | 190M | 455M | 527M | 1.20B |
| Shareholders' Equity | - | - | - | 279M | 462M | 544M | 288M | 3.20B | 3.26B | 3.26B |
| Cash & Short-term Investments | - | - | - | 65.3M | 295M | 346M | 124M | 362M | 294M | 301M |
| Total Debt | - | - | - | 19.7M | 17.0M | 20.7M | 71.3M | 304M | 250M | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | - | - | - | - | 182M | 161M | 42.6M | 56.0M | 157M | 223M |
| Capital Expenditure | - | - | - | 0.00 | 1.71M | 9.80M | 2.59M | 46.2M | 124M | 104M |
| Free Cash Flow | - | - | - | - | 180M | 151M | 40.0M | 9.75M | 33.2M | 119M |
| Ratios | ||||||||||
| ROE | - | - | - | 13.7% | 27.2% | 31.0% | 10.4% | 1.4% | 3.6% | 3.1% |
| ROA | - | - | - | 12.0% | 24.6% | 27.8% | 6.3% | 1.3% | 3.1% | 2.3% |
| Net Profit Margin | -83.8% | -96.3% | -12.4% | 22.2% | 40.0% | 44.4% | 7.1% | 8.1% | 12.2% | 10.2% |
| Debt to Equity | - | - | - | 0.07x | 0.04x | 0.04x | 0.25x | 0.09x | 0.08x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
SunWay Biotech Co., LTD. dividends
- Dividend yield
- 1.87%
- Forward dividend
- 0.78 TWD
- Payout ratio
- 79.1%
- Ex-dividend date
- Jul 30, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | TWD 80.3M | 1.34 | 79.1% |
| 2024 | TWD 59.4M | 0.98 | 50.1% |
| 2023 | TWD 42.7M | 1.39 | 92.5% |
| 2022 | TWD 6.44M | 0.32 | 21.4% |
| 2021 | TWD 92.7M | 2.70 | 54.9% |
| 2020 | - | - | - |
| 2019 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1016.83813:1000 on Dec 9, 2024.
Who owns SunWay Biotech Co., LTD.
Ownership data of SunWay Biotech Co., LTD. is not available yet.
SunWay Biotech Co., LTD. company profile
- Company name
- SunWay Biotech Co., LTD.
- Ticker
- 1271.TWO
- ISIN
- TW0001271005
- Exchange
- Taiwan OTC Exchange
- Sector
- Consumer Defensive
- Industry
- Packaged Foods
- Fiscal year end
- December
- Address
- No. 358, Gongjian Road, Taipei, Taiwan, 22161
- Phone
- 886 2 2792 9568
- Website
- sunway.cc
About SunWay Biotech Co., LTD.
SunWay Biotech Co., LTD. engages in the research, development, manufacture and sales of Western medicines and health foods. The company offers red yeast rice and lactic acid bacteria products, as well as other health supplements; and wholesale and manufacturing of pharmaceutical products. It also research, designs, and manufactures Monascus purpureus NTU 568; Lactobacillus paracasei subsp. paracasei NTU 101; Monascus pilosus SWM-008 strain; Pediococcus acidilactici SWP-CGPA0; Levilactobacillus brevis SWP-TKLB01; and other and related products. The company was founded in 2007 and is based in Taipei, Taiwan.
SunWay Biotech Co., LTD. management
6- Mr. Pei-Chi ChenChief Executive Officer · born 1967
- Mr. Jia-Yue PanVice Chairman & President
- Brett KoChief Financial Officer
- Yuanchang ZhengAccounting Supervisor
- Prof. Tzu-Ming PanChief Technology Officer
- Jenny SungConsumer Healthcare Head